Top Medical News
Yesterday
Fatty liver disease is strongly associated with an increased risk of developing erosive oesophagitis, a study suggests.
Pearl Toh, 4 days ago
Liraglutide was as effective as a structured supervised lifestyle modification programme combining diet and exercise for reducing weight, liver damage, and liver fat at 26 weeks in obese Asians with nonalcoholic fatty liver disease (NAFLD), a study shows.
Tristan Manalac, 6 days ago
While liraglutide successfully induces weight loss in obese adults with nonalcoholic fatty liver disease (NAFLD), its benefits were not preserved after discontinuation, unlike that of lifestyle modification, according to a new Singapore study.
08 Feb 2019
Exposure to nonselective beta blockers contributes to an increased risk of developing portal vein thrombosis in patients with cirrhosis, a study suggests.
07 Feb 2019
Statin provides about an 8-percent annual reduction in mortality in patients with cirrhosis, a study has found. Furthermore, exposure to the drug is associated with a lower risk of developing hepatic decompensation events and liver cancer among those with well-compensated disease, but does not yield any survival benefit in those with advanced decompensated disease.
17 Jan 2019
Baseline nonalcoholic fatty liver disease activity score (NAS), concentration of triglycerides and decreasing alanine aminotransferase levels all predicted the response of nonalcoholic steatohepatitis (NASH) patients to obeticholic acid (OCA), a recent study has shown.
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.

Special Reports
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
Conference Reports
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

Roshini Claire Anthony, 19 Feb 2018

Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.

Jackey Suen, 25 Oct 2017

Eradication of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is becoming achievable, although much work still has to be done, says an expert.

Jackey Suen, 24 Oct 2017

Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.

04 Oct 2017
Slideshow: Highlights from the Asia Pacific Digestive Week 2017 (APDW 2017)
Naomi Rodrig, 03 Oct 2017

An index of three liver-specific microRNAs (the MiR-B Index) could serve as a biomarker of spontaneous or treatment-induced transition from active to inactive chronic hepatitis B virus (HBV) infection, facilitating disease monitoring and testing of new antivirals, according to Dr Mauricia Brunetto from the University of Pisa, Italy, who spoke recently at the Asian Pacific Digestive Week (APDW) 2017 in Hong Kong.

Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download